Stockholders Approve New Incentive Plans Authorizing 925,000 Shares Amidst Pending Merger

summarizeSummary

Stockholders approved new incentive plans authorizing 925,000 additional shares, representing a potential 7.76% dilution, amidst a pending merger agreement with Ligand Pharmaceuticals.

check_boxKey Events · Financing and Capital Events · XOMA

• Share Plan Expansion Approved

  Stockholders approved an amendment to the 2010 Long Term Incentive and Stock Award Plan, increasing available shares by 425,000, and a new 2026 Employee Stock Purchase Plan (ESPP) for 500,000 shares.

• Significant Potential Dilution

  These approvals authorize a total of 925,000 new shares, representing a potential dilution of approximately 7.76% based on the 11,915,730 shares outstanding as of March 25, 2026.

• Merger-Related Bylaw Amendments Adopted

  The Board adopted amendments to the company's bylaws, including provisions related to Nevada controlling interest statutes and an exclusive forum for certain legal claims, in connection with the pending merger with Ligand Pharmaceuticals.

• Annual Meeting Results Confirmed

  All director nominees were elected, and all other proposals, including auditor ratification and executive compensation (advisory), were approved by stockholders.

auto_awesomeAnalysis · XOMA · Life Sciences

XOMA Royalty Corp's stockholders approved an increase of 925,000 shares for its long-term incentive and employee stock purchase plans. This represents a potential dilution of approximately 7.76% of current outstanding shares. While the company has a pending merger agreement with Ligand Pharmaceuticals, the market is currently trading above the $39 per share offer price, suggesting uncertainty about the merger's completion or terms. If the merger does not close, this authorization could lead to significant dilution for existing shareholders. The company also adopted bylaw amendments related to the merger, including exclusive forum provisions.